IBSA: INNOVATION IN OSTEOARTICULAR INFILTRATION THERAPY

IBSA has specialised in the production of HYALURONIC ACID for 15 years
From microbial fermentation | Highly purified | Entirely manufactured in Italian factories

GENERATIONS OF HYALURONIC ACID

1st generation

LINEAR HYALURONIC ACID

High molecular weight HA (800 - 1,200 kDa)

2nd generation

HYBRID HYALURONIC ACID

Stable hybrid cooperative complexes of high molecular weight HA (1,400 kDa) and low molecular weight HA (80 kDa)

3rd generation

COMBINED HYBRID HYALURONIC ACID

Stable hybrid cooperative complexes of high molecular weight HA (1400 kDa) and biotechnological sodium chondroitin (40 kDa)

IBSA COMMITMENT TO
HYALURONIC ACID PRODUCTION

IBSA has developed an innovative patented microbial process to produce highly purified hyaluronic acid with controlled molecular weight. The obtained hyaluronic acid has high purity and a controlled distribution of the desired molecular weight.

In visco-supplementation therapy for the treatment of joint diseases such as osteoarthritis, it is important that the properties of the hyaluronic acid solution administered are similar to those of natural hyaluronic acid found in synovial fluid.

Therefore IBSA has developed and patented

NAHYCO® HYBRID TECHNOLOGY allows to deliver high doses of hyaluronic acid, optimising the viscous and elastic properties of the formulation and improving its resistance to degradation. This process is based on an innovative thermal system that avoids the use of chemical reagents and enables the creation of hybrid cooperative complexes of high and low molecular weight molecules, effectively reproducing the physical and mechanical properties of healthy synovial fluid and optimising the concept of visco-supplementation.

 

PRODUCTS

IBSA specialises in research and development,
production and marketing of hyaluronic acid-based products.